China Shineway Pharmaceutical Group Ltd. has announced its turnover for the first quarter of 2025, reporting actual results that show a significant decline in sales compared to the same period in 2024. The company's turnover for the three months ended March 31, 2025, amounted to RMB761 million, marking a decrease of 31.9% from the previous year. The breakdown of the turnover reveals that injection products saw a decrease of 35.5%, amounting to RMB262 million. Soft capsule products experienced a substantial drop of 52.9%, with a turnover of RMB81 million. Granule products reported a decrease of 41.2%, reaching RMB117 million, while TCM formula granule products saw a decline of 13.8%, totaling RMB244 million. Products in other forms decreased slightly by 1.7%, with a turnover of RMB57 million. In terms of product mix for the first quarter of 2025, injection products accounted for approximately 34.4% of the total turnover, soft capsule products for 10.6%, granule products for 15.4%, and TCM formula granule products for 32.1%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.